SCHEMBL10107592

SCHEMBL10107592

C=C(C)OC(=O)N1CCC(CN(CC)Cc2nc(-c3ccncc3)no2)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.49
LMNA P02545 6/20 0.44
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.42
TSHR P16473 3/20 0.42
MAPK1 P28482 1/20 0.40
RECQL P46063 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CHRNA7 P36544 1/20 0.39
HTT P42858 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HPGD P15428 1/20 0.38
THRB P10828 1/20 0.38
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL390037 0.87 GPR119 (0.66) GPR119LMNAALDH1A1KMT2AMEN1
SCHEMBL1831648 0.86 GPR119 (0.48) GPR119LMNAALDH1A1KMT2AMEN1
SCHEMBL10107355 0.82 GPR119 (0.52) GPR119LMNAALDH1A1KMT2AMEN1
SCHEMBL10107598 0.82 GPR119 (0.57) GPR119LMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL27951715 0.81 GPR119 (0.49) GPR119LMNAALDH1A1KMT2AMEN1
SCHEMBL10107534 0.78 KMT2A (0.61) GPR119LMNAALDH1A1KMT2AMEN1
SCHEMBL389185 0.76 GPR119 (0.68) GPR119LMNAALDH1A1KMT2AMEN1
SCHEMBL2292951 0.75 GPR119 (0.49) GPR119LMNAALDH1A1KMT2AMEN1
SCHEMBL390149 0.74 GPR119 (0.51) GPR119LMNAALDH1A1KMT2AMEN1
SCHEMBL10107332 0.74 GPR119 (0.60) GPR119LMNAALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207147-B2 Heterocyclic derivatives as GPCR receptor agonists PROSIDION LIMITED (GB) 2012-06-26 US disclosed
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281060-A1 HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS GPR119, GCGR, GLP1R GPR119 1/4885LMNA 4276/4885ALDH1A1 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.